Cardiovascular Profile of Pharmacological Agents Used for the Management of Polycystic Ovary Syndrome
January 2019
in “
Therapeutic Advances in Endocrinology and Metabolism
”
polycystic ovary syndrome PCOS oral contraceptives antiandrogens clomiphene metformin glitazones dipeptidyl peptidase IV inhibitors glucagon-like peptide-1 receptor agonists flutamide pioglitazone incretin mimetics SGLT2 inhibitors birth control pills Clomid Glucophage thiazolidinediones DPP-4 inhibitors GLP-1 receptor agonists Eulexin Actos
Studysummary This review found no evidence that medications used to manage PCOS add to cardiovascular risk or prevent diabetes onset, although metformin may help prevent gestational diabetes in these patients.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on journals.sagepub.com →